Horizon Therapeutics to make blockbuster out of Genmab drug in 2021

Tepezza can already boast one of the best launches ever for a rare disease drug, and current owner company Horizon Therapeutics forecasts that the drug, developed in Genmab's labs, will sell for more than a billion US dollars in 2021.
Photo: PR / Genmab
Photo: PR / Genmab

US-based biopharmaceutical company Horizon Therapeutics is pulling out the big guns to market its rare disease drug, Tepezza, originally developed in the laboratories of Danish biotech firm Genmab.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading